The agreement with Taiwan's Prisma Biotech is the second distribution deal in Asia for Intermountain Precision Genomics' ICG100 tumor sequencing test.
Clinicians and genetic counselors are coming up with triage strategies for cancer cases in which medically actionable germline mutations are suspected.
IDB Resources will offer Paradigm Diagnostics' PCDx NGS tumor profiling test in Malaysia, Singapore, and Brunei.
Strata said it will use the funds to implement the Strata Trial, a nationwide effort to increase the number of enrollments in precision medicine clinical trials.
Genetic Alliance researchers have come up with recommendations for the UK's NHS on how to incorporate whole-genome sequencing into standard cancer care.
Researchers from St. Jude Children's and the German Cancer Research Center used methylation and gene expression analyses to uncover the subtypes.
The Belgian cancer diagnostics firm will provide the lab with access to its OncoDeep DX Plus and Clinical Plus services.
Both studies found that about 40 percent of pediatric cancer patients have mutations with potential clinical significance, either for diagnosis or treatment.
The researchers performed targeted sequencing using Thermo Fisher Scientific's Oncomine Comprehensive Panel and the Ion Torrent PGM or Proton.
The partners will develop an NGS panel for solid and liquid tumors for use in personalized oncology.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.